Abstract The commercial polymerase chain reaction (PCR) test, SeptiFast, is designed to identify the DNA of individual bacterial and fungal pathogens in whole blood. We aimed to evaluate the usefulness of the test for the detection of community-onset bloodstream infections. We prospectively included adult patients who were subjected to blood culture (BC) at an infectious diseases department. For the evaluation, one BC/PCR set (two BC bottles and one PCR tube) per patient was used. When several sets were obtained and analyzed, the first set with any positive result was evaluated. Among 1,093 consecutively included patients, BC was positive in 138 and PCR was positive in 107. Fifty positive PCR results were supported by BC in the same BC/PCR set, ten were supported by other cultures, and, additionally, ten were supported by the clinical presentation. Compared with BC, PCR showed specificities and negative predictive values of >97% for all detectable pathogens. The following sensitivities and positive predictive values (PPVs) were noted: Staphylococcus aureus, 67% and 43%; Streptococcus pneumoniae, 12% and 67%; other Streptococcus species, 43% and 77%; Escherichia coli, 53% and 56%; and Klebsiella species, 43% and 23%. If support from other cultures and the clinical presentation were included in the reference standard, the PPVs for the detection of these bacteria were 57%, 100%, 92%, 75%, and 69%, respectively. Although the specificities were high, the low sensitivities and suboptimal PPVs noted in the present study discourage routine use of the test in its present form for the detection of community-onset bloodstream infections.
Introduction
Bloodstream infections are important causes of morbidity and mortality in patients worldwide. Rapid etiological diagnosis and the early administration of adequate antimicrobial therapy soon after a critically ill patient's arrival at the hospital are important for a successful outcome [1, 2] . Inadequate antimicrobial treatment has been reported to be associated with increased mortality [3, 4] .
Blood culture (BC) is, at present, considered to be the diagnostic gold standard for bloodstream infections, with high specificity in species identification. However, slowgrowing and fastidious organisms can delay diagnosis and prior antimicrobial treatment reduces the sensitivity of the BC method.
New non-culture-based techniques are, consequently, being developed for the diagnosis of septicemia/bacteremia [5] [6] [7] . One of the approaches for potentially faster pathogen identification is to use target-amplification methods, including molecular amplification with polymerase chain reaction (PCR). General methods that use genes for ribosomal RNA can create problems with contaminating bacteria, causing impaired analytical specificity and sensitivity [8] . A new commercially available multiplex PCR (SeptiFast, Roche Diagnostics GmbH) with the potential to identify 19 different bacterial species and six fungal species in whole blood has been developed [9] . The aim of the present prospective, diagnostic study was to evaluate this new PCR by comparing it with BC in a large, consecutive, non-selective group of adult patients seen at a department of infectious diseases in southern Sweden. We estimated that about 1,000 different patients would be subjected to BC during one year, with about 100 positive BCs.
Materials and methods

Patients
The Department of Infectious Diseases, Örebro University Hospital, Sweden, provides service for a population of 275,000 inhabitants in the county of Örebro and has a ward with 30 beds for adults and an outpatient clinic.
In the present prospective study, we enrolled all adult patients who were subjected to BC at the department and gave their informed consent during one full year from October 2007 to September 2008. Excluded were patients with HIV and with hepatitis B and C infections for local laboratory safety reasons.
SeptiFast method
Whole blood was collected in sterile EDTA tubes (BD Vacutainer™ K3E 15%, Becton, Dickinson and Company, Plymouth, UK) through the same venepuncture from which the blood samples for BC were taken. The whole blood was then stored for a maximum of 4 h at room temperature, or up to 3 days at +4°C, or 3 months at −70°C prior to DNA preparation. The DNA preparations were handled identically.
The internal transcribed spacer (ITS) region is used in the SeptiFast assay (Roche Diagnostics GmbH, Mannheim, Germany) as the target to specifically distinguish 25 different bacterial and fungal pathogens (see Table 1 ). As the detection format, hybridization probes are used.
DNA was extracted from 1.5 ml of an EDTA wholeblood sample. The protocol of the manufacturer was followed, including a first step of mechanical lysis using the SeptiFast Lys Kit MGRADE and the MagNA Lyser®. The DNA was prepared manually using the SeptiFast Prep Kit MGRADE (Roche Diagnostics GmbH). In the extraction step, an internal control (IC) was added to each sample. The IC is a mixture of synthetic doublestranded DNA molecules with primer binding sites identical to those of the target sequences, differing in their probe binding sites. A negative control supplied by the manufacturer was included in each extraction series and the reagent controls were used as the positive control of the PCR reactions. Gram-positive bacteria, Gramnegative bacteria, and fungi were amplified individually in three different mixes. The real-time PCR was performed in a LightCycler 2.0 instrument (Roche Diagnostics GmbH). The emitted fluorescence was measured in one of the four different detection channels (610, 640, 670, and 705 nm). Analysis of the melting curves were performed to strengthen the specificity of the products. The PCR amplicons from the specimens and ICs were analyzed by pathogen identification software (SIS; SeptiFast Identification Software, Roche Diagnostics GmbH). The software automatically calculated the melting point (Tm) value and the corresponding peak height. For the Gram-positive assay, the analysis was based on melting peaks (Tm and peak height) and amplification curve crossing point (Cp) values. The assays for Gram-negative and fungi were solely based on melting peaks and Cp values were not considered. To reduce false-positive results by assumed contaminants, the software also includes Cp cut-off values, e.g., for coagulase-negative Staphylococcus (CoNS) and Streptococcus species, this cut-off value is at 20 cycles. The assay was flagged as "Invalid" if the software could identify neither a specimen nor the IC. The turnaround time was 6 h. The results of the PCR assays were unknown to the clinicians until the closure of the study.
Blood culture BC was performed with the Bactec system (Becton, Dickinson and Company, Sparks, MD, USA) as a standard procedure in patients with suspected disseminated bacterial and/or fungal infection. For each BC, a volume of 8-10 ml of venous blood was inoculated in one Bactec Plus Aerobic/F bottle and the same volume in one Bactec Plus Anaerobic/F bottle. After transport at room temperature, the bottles were placed in a Bactec 9240 incubator, with monitoring for pH changes every 10 min for 6 days.
All signaling bottles were opened and an aliquot was taken for microscopy after Gram staining, culture on solid media, and further analyses for species designation according to the good laboratory practice of our accredited clinical diagnostic microbiological laboratory.
Other cultures
Cultures from normally sterile sites and from urine, wounds, and respiratory secretions were performed according to standard microbiological procedures [10] . The choices of performing such cultures were based on the clinical judgement of the clinicians.
Clinical data
At inclusion, clinical data were collected, including information on whether antibiotics had been taken within 3 days prior to BC. A retrospective chart review was performed by two specialists of infectious diseases (P.J., K.S.).
Analysis
The SeptiFast results were compared with the results of BC and other microbiological data. Although we routinely collected paired BC, we included for evaluation only one BC/PCR set (two BC bottles and one PCR tube taken at the same time) per patient. If it was not negative in these analyses, the first BC/PCR set providing any positive result was included.
Definitions
A positive PCR result was considered to be fully supported when an identical microorganism was isolated in the BC of the same BC/PCR set. Other microbiological support for a positive PCR was defined as other positive BCs, cultures from normally sterile sites and from bronchial secretion, and pure culture in urine and wounds. Wound culture with mixed flora including Staphylococcus aureus and β-hemolytic streptococci was also regarded as other microbiological support.
In the cases of a positive PCR result without any microbiological support, we made a retrospective attempt to find clinical support for the positive PCR result. We considered a PCR result to have clinical support if the species identified by PCR was generally considered to be a common pathogen of the patient's type of infection, and if no microbiological support for any other pathogen was identified.
The regional ethical committee approved the study.
Results
During the study period, the total number of patients subjected to BC at the department was 1,540, and a positive BC was found in 208 of them. Altogether, 1,093 patients were included in the present study, comprising 486 females (44%) and 607 males (56%). All of these patients had results from at least one BC/PCR set. Of the included patients, the median age was 67 years (range 14-98 years). Intensive care unit (ICU) support was received by 36 patients. The crude mortality rate within 30 days was 45/1,093 (4%).
Blood culture and/or PCR was positive for any pathogen in 197 patients (18%), and in 896 patients, the BC/PCR sets were negative. A positive BC was found in 138 of the patients and 107 patients had positive SeptiFast results.
The results regarding the pathogens detected by BC and/or PCR for species included in the PCR test menu are summarized in Table 2 . The most commonly detected pathogens were CoNS, Staphylococcus aureus, Streptococcus pneumoniae, other Streptococcus species, Escherichia coli, and Klebsiella species. The results from patients who received antibiotic treatment within 3 days prior to BC are shown for each pathogen. In total, there were 50 results that were positive in both PCR and BC, 64 results that were positive only with PCR, and 86 results that were positive only with BC among the pathogens on the PCR test menu.
Concerning CoNS, ten were positive only with PCR, 30 were positive only with BC, and only one was positive with both PCR and BC. It may also be noted that, for Streptococcus pneumoniae, 14 were positive only with BC, one was positive only with PCR during antibiotic treatment, and two were positive with both PCR and BC. Regarding other Streptococcus species, 13 were positive only with BC, among which four were positive for Streptococcus pyogenes and seven were positive for other β-hemolytic streptococci (one of which with an invalid result in PCR). Three results were positive for other Streptococcus species by PCR only. PCR and BC were positive for ten results, and, of these, two were positive for Streptococcus pyogenes and four were positive for other β-hemolytic streptococci according to BC.
With BC, ten different isolated pathogens that are not included in the PCR test menu were also found in ten patients. They were Aerococcus viridans, Arcanobacterium haemolyticum, Pseudomonas fluorescens, Shigella flexneri, Bacteroides species, Citrobacter species, Corynebacterium species, Fusobacterium species, Porphyromonas species, and Salmonella species.
Polymicrobial results were obtained in 12 patients, and are shown in Table 3 .
In Table 4 , the PCR-positive results are compared with the results of BC and other cultures in an attempt to find other support for a positive PCR result. In the cases of positive PCR without microbiological support, clinical support is presented. For Staphylococcus aureus, other microbiological support was, in one case, another positive BC and a positive joint culture; in one case, another positive BC and culture from cerebrospinal fluid; and, in one case, a positive culture from a renal cortical cyst. For Streptococcus species, other microbiological support consisted of wound culture, including β-hemolytic streptococci in two cases. Other microbiological support was other positive BC in two cases for Escherichia coli, and other positive BC in two cases and in one case pure culture in urine for Klebsiella.
Positive PCR results without any microbiological or clinical support were obtained, for example, with CoNS in ten cases, Staphylococcus aureus in ten cases, Escherichia coli in eight cases, and Pseudomonas aeruginosa in four cases.
In total, there were 114 positive PCR results from 107 patients, and 50 of them were fully supported by BC in the same BC/PCR set, and ten by other cultures; additionally, ten results were supported by the clinical presentation. In 44 cases, no microbiological or clinical support was found.
Compared with BC, the SeptiFast test showed specificities of over 98% and negative predictive values of over 97% for all detectable pathogens. In Table 5 , the sensitivities and positive predictive values (PPVs) are presented for major bacterial pathogens. PPVs are also shown with a combined reference standard including other microbiological support and clinical support.
Discussion
The theoretical advantages of a non-culture diagnostic method such as PCR for bacteremia, as compared to normal BC, include a substantially shorter time for reporting the test result (both positive and negative) and the detection of DNA in the blood without live microorganisms after, for example, antibiotic treatment.
The development of PCR tests for the diagnosis of bacteremia is, hence, of great clinical interest and assays have been designed and tested without a major breakthrough so far. The problems include the large number of bacterial species (and fungi) that are clinically relevant, the sometimes minute amounts of microbial DNA as compared to the huge amount of human DNA, and contaminants in connection with the blood sampling from the skin and the further handling.
When a commercial test (SeptiFast) with a promising design was launched, the need for an evaluation was evident. We thus chose to study an unselected group, aiming at including all adult patients seeking medical attention at our department of infectious diseases, for whom a blood culture was ordered during one full year.
In the present study, there was no systematic loss of patients for inclusion. A loss was seen, however, in a few situations of overload of the department, and as a result of some mistakes in the sampling; also, a few single patients chose not to participate. Our handling of samples and our laboratory work strictly followed the instructions from the manufacturer of SeptiFast. In order not to create any bias, only one set of BC/PCR per patient was included for evaluation.
With this approach, we consider the patient material to be representative of a population that, in most cases, reaches the hospital with an infection that they have developed outside the healthcare systems, termed community-onset blood stream infection.
In the design of the SeptiFast test, the ITS region has been selected as the target region. By this approach, a higher sensitivity can be achieved compared to single-copy genes, since there are often several ribosomal operons in the genomes of bacteria and fungi [9, 11] . A higher specificity can also be obtained compared to rRNA, as the ITS is more species-specific.
The selected species of bacteria and fungi that can be identified by SeptiFast was calculated to leave about 10% of our bacteremias undiagnosed. Important pathogens are missing, such as the anaerobes, Salmonella, Shigella, Haemophilus species, and Neisseria meningitidis. In our study, 10 results (7%) out of 146 positive BCs, from 138 patients, included pathogens not covered by the SeptiFast.
In the evaluation, the results with the different diagnostic systems must also take into account that the blood culture system uses 8-10 ml of venous blood per bottle (one aerobic and one anaerobic bottle is taken in each culture), compared to the SeptiFast test, which uses 1.5 ml in an EDTA tube with vacuum for the preparation of a DNA extract for six PCR assays. One PCR assay, thus, contains DNA from 0.25 ml of blood or 1:32-40 of the blood culture volume used in one bottle. This may have had implications for the diagnostic sensitivity.
In the SeptiFast assay, high-quality PCR reagents, free of bacterial or fungal DNA contamination, are used according to the information provided by the producer. The EDTA vacuum tubes for drawing venous blood were recommended by the producer and is said to be endotoxin-and DNA-free. The present study results indicate, however, that contamination was a problem, giving false-positive Escherichia coli PCR results in some cases (8 out of 32 had no support for the positive PCR result; Table 4 ) and Pseudomonas aeruginosa in a few other cases (4 of 6 without support; Table 4 ). Whether these contaminants came from the sampling tubes or the reagents is not clear. Such problems have to be brought down to an absolute minimum by the producers.
The background of a negative result with SeptiFast, despite positive BC with a bacterium that is included in the test (false-negative), is multifactorial. The reasons for this may be speculated upon and include possibly less optimal technical steps in the PCR reaction, incorrect interpretation of amplification signals, problems with the selection of species-specific targets in the test, and the blood volume used.
In the present study, the SeptiFast false-negative Streptococcus pneumoniae bacteremic cases are most noteworthy, since only 2 of 16 BC-positive samples were detected, i.e., the sensitivity was 12%. This may be explained by the fact that the manufacturer of SeptiFast has set the detection level for Streptococcus pneumoniae high, in order not to have false-positive results caused by closely related α-hemolytic streptococci. For the optimal detection of Streptococcus pneumoniae DNA, PCR targets specific to Streptococcus pneumoniae should probably be used. We recently found that PCR for lytA applied to plasma samples had a sensitivity of 70% and a specificity of 99% for the detection of Streptococcus pneumoniae bacteremia in patients with community-acquired pneumonia [12] . The same problem was encountered for other bacteremic streptococci, mainly β-hemolytic ones, which were negative in 57% in the SeptiFast test.
These results hamper the use of the tested version of SeptiFast for the detection of bacteremia in a general infectious disease patient population, where pneumococci and invasive hemolytic streptococci are common causes of community-onset bacteremia.
A positive result with SeptiFast when the BC is negative can be received in a number of situations. Some of these results are clinically reliable and helpful, and some are misleading.
A well-defined contribution by the nucleic assay tests is the performance when antibiotics have been given prior to culture, and individual patients in this situation were seen in the present study ( Table 2) .
The presence of bacterial/fungal DNA in whole blood without live organisms has not, so far, been systematically explored. Biologically, it is a likely situation that could focus an investigation on a search for a localized infection. The present study includes such patients, for example, with Staphylococcus aureus positivity in SeptiFast (Table 4) .
Contamination of a blood sample as such in connection with the sampling of the patient involves the skin flora from which mainly different staphylococci and streptococci become positive in the diagnostic systems. The results for CoNS in the present study (Table 2) indicate that there are problems with skin contamination. Both nucleic assay tests and culture systems share these problems and results have to be repeated in order to be more reliable. A semiquantitative view is also useful in these situations when a late and low PCR product and a need for long-term incubation for growth favor the judgement of a contaminant [13, 14] .
A number of studies, mainly with smaller study groups, using SeptiFast for the detection of microbial DNAemia, have been published with various results. Several publications have focused on compromised and highly selected patient groups, mainly from hematological units [15] [16] [17] [18] [19] .
Some publications include community-onset bloodstream infections. Louie et al. studied 200 adult patients, sampled in emergency rooms, intensive care units, and general medicine wards. They found positive PCR in 45 cases compared to 37 BC, and 69% of the PCR results were confirmed by blood, urine, and catheter culture [20] . Tsalik et al. included 306 patients with suspected sepsis. In the patients with an identified infectious etiology, 66 were positive with BC and 46 with PCR [21] . Avolio et al. compared BC with SeptiFast in patients admitted to the emergency room with suspected sepsis. Out of 144 samples, 30 identified the same organism with BC and PCR, 13 organisms were identified only with BC, and ten were positive only with PCR [22] . Westh et al. conducted a multicenter trial of patients with suspected bacterial or fungal septicemia. In total, 359 patients were evaluated. The rate of positivity was 17% for BC and 26% for SeptiFast. The 74 non-contaminant BC isolates were identified with PCR in 50 cases. The 174 noncontaminant microorganisms detected by SeptiFast were isolated by BC in 50 cases and, additionally, 67 could be confirmed as probable clinical pathogens by the culture of the same microorganism from a relevant anatomical site within the same clinical time frame. No support was found for a total of 57 samples [23] .
In the present study, we found that the positivity rate of PCR was generally slightly lower than that of BC. In agreement with the previous studies on the SeptiFast test, we found that the test had high specificities and high negative predictive values for the detectable pathogens. However, the sensitivities and PPVs of the test were suboptimal, facts that became obvious with the layout of our study, with a large number of community-onset consecutive patients.
